Benutzer: Gast  Login
Titel:

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease.

Dokumenttyp:
Article; Journal Article; Research Support, Non-U.S. Gov't
Autor(en):
Sachs, Stephan; Götz, Anna; Finan, Brian; Feuchtinger, Annette; DiMarchi, Richard D; Döring, Yvonne; Weber, Christian; Tschöp, Matthias H; Müller, Timo D; Hofmann, Susanna M
Abstract:
BACKGROUND: Agonism at the receptor for the glucose-dependent insulinotropic polypeptide (GIPR) is a key component of the novel unimolecular GIPR:GLP-1R co-agonists, which are among the most promising drugs in clinical development for the treatment of obesity and type 2 diabetes. The therapeutic effect of chronic GIPR agonism to treat dyslipidemia and thus to reduce the cardiovascular disease risk independently of body weight loss has not been explored yet. METHODS: After 8 weeks on western diet...     »
Zeitschriftentitel:
Cardiovasc Diabetol
Jahr:
2023
Band / Volume:
22
Heft / Issue:
1
Volltext / DOI:
doi:10.1186/s12933-023-01940-2
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/37592302
Print-ISSN:
1475-2840
TUM Einrichtung:
602; Lehrstuhl für Stoffwechselerkrankungen (Prof. Tschöp)
 BibTeX